Explorez tous les épisodes du podcast NeuroFrontiers

Joseph Sullivan, MD, Professor, UCSF School of Medicine, San Francisco, CA, describes encouraging results from the SWALLOWTAIL and LONGWING studies of an investigational treatment for individuals with Dravet syndrome, including outcomes related to seizure frequency, cognition, and behavior.

Stavros Zanos, MD, PhD, Associate Professor, Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, uses neurostimulation as a means to study the nervous system and to treat diseases in which the nervous system is affected or implicated. In this episode, Dr. Zanos gives an overview of the current understanding of Vagus Nerve Stimulation and shares important updates for future research and treatments beyond the nervous system.

Paul Kruszka, MD, Chief Medical Officer at GeneDx, discusses advanced genomic testing, emphasizing how these tests are used to guide diagnosis and treatment decisions associated with neurodevelopmental conditions, including genetic variants associated with epilepsy.

Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of treatment and recovery options available to physicians with substance use disorder, including peer-to-peer support, medication, and Physician Health Programs.

Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of physician substance use disorder, including prevalence, risk factors, and impediments to recovery as well as details about his own journey with recovery.

In this episode, Trisham Gyang, MD, Clinical Assistant Professor of Neurology, The Ohio State University Wexner Medical Center, and Gopika Govindan Kutty, MD, Fellow, Department of Neurology, The Ohio State University Wexner Medical Center, provide strategies to assess biologic, genetic, and social factors in patients living with MS to help shrink the gap in care for underrepresented populations.

Jack Reeves, PhD, researcher at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, discusses results of a study which demonstrated high efficacy disease-modifying therapies may help prevent the development of paramagnetic rim lesions and slow the progression of multiple sclerosis.

Preventable harm is a serious concern for patients with Parkinson disease who receive care in the hospital setting, even when admitted for reasons other than their diagnosis. Peter Pronovost, MD, PhD, FCCM, Chief Quality and Transformation Officer at University Hospitals Cleveland Medical Center, Cleveland, OH, discusses his work with the Parkinson’s Foundation developing new hospital care standards for reducing medication mismanagement and improper or insufficient care.

Beth McQuiston, MD, RD, Medical Director, Abbott, Abbott Park, IL, and David Okonkwo, MD, PhD, Professor of Neurological Surgery, University of Pittsburgh, Pittsburg, PA, describe some of the important updates to guidelines for the assessment of traumatic brain injury, including biomarker testing.

Jae W. Song, MD, MS, Associate Professor of Radiology at the University of Pennsylvania, Philadelphia, PA, discusses the diagnostic value of intracranial vessel wall MRI for vasculitis, as well as when clinicians should order this imaging technique and the challenges that may arise.

Riley Bove, MD, UCSF School of Medicine, San Francisco, CA details results from the MINORE and SOPRANINO studies examining Ocrevus treatment in pregnant and lactating women with multiple sclerosis.

Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapy for individuals with generalized myasthenia gravis and its impact on outcomes and steroid reduction in real-world practice. Additional details about MINT may be found in the following publication: The New England Journal of Medicine. For more information on the medication discussed in this episode, please refer to the Full Prescribing Information provided by Amgen, last updated 12/2025.

In this episode, Luka Kulic, MD, Vice President and Global Head of Early Clinical Development in Neuroscience and Rare Diseases at Roche, Basel, Switzerland, discusses the investigational Brainshuttle technology, including results from the BrainShuttle AD clinical trials as a treatment for early Alzheimer disease along with the broader implications of enhanced blood-brain barrier drug delivery in neurology.

Episode Description: What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.